drugset
drugset / Trial / NCT02005757

Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)

NCT02005757 ↗

Phase 2 Unknown 60 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to access the efficacy and safety of Mizoribine 150mg qid and 50mg tid in active rheumatoid arthritis patients unsuccessfully treated with disease-modifying antirheumatic drug.

Timeline

Start
2013-11
Primary completion
2016-06
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mizoribine Small molecule 50 mg —
Subject Mizoribine Small molecule 150 mg —

Indications

rheumatoid arthritis